Clinical Trial

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Study acronym: EVOLVE
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participants receiving eteplirsen, golodirsen, and casimersen in routine clinical practice. Participants in this study will have been prescribed eteplirsen, golodirsen, or casimersen commercially prior to entry into the study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-19.
Trial Details
NCT Number NCT06606340
Lead Sponsor Sarepta Therapeutics, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 300 participants
Start Date 2019-01-07
Primary Completion 2033-12-31 (estimated)
Study Completion 2033-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-10